8/4/2025

Fluocinolone Acetonide Intravitreal Implant

Products Affected - Description

- Yutiq intravitreal implant, Ani Pharmaceuticals, 0.18 mg prefilled syringe, 1 count, NDC 68611-0180-01

Reason for the Shortage

- Ani Pharmaceuticals did not provide a reason for the shortage.

Available Products

- Iluvien intravitreal implant, Ani Pharmaceuticals, 0.19 mg prefilled syringe, 1 count, NDC 68611-0190-02

Estimated Resupply Dates

- Ani Pharmaceuticals has Yutiq 0.18 mg intravitreal implant on long term back order and the company cannot estimate a resupply date.

Implications for Patient Care

- Fluocinolone acetonide intravitreal implant is used for patients with chronic non-infectious uveitis affecting the posterior segment of the eye. [1-3]
- Iluvien is also used for specific patients with diabetic macular edema. [1]

Alternative Agents & Management

- Both Yutiq 0.18 mg and Iluvien 0.19 mg deliver fluocinolone acetonide at an initial rate of 0.25 mcg/day for 36 months. [1, 2]
- Bausch Health has Retisert 0.59 mg available, which delivers fluocinolone acetonide at an initial rate of 0.6 mcg/day in the first month and a steady-state rate of 0.3-0.4 mcg/day for 30 months. [3]
- Retisert is surgically implanted into the posterior segment of the eye via an incision, while Iluvien and Yutiq are injected into the vitreous cavity. [1-3]

References

1. Iluvien [package insert]. Alpharetta, GA: Alimera Sciences, Inc., 202.
2. Yutiq [package insert]. Alpharetta, GA: Alimera Sciences, Inc. , 2023.
3. Retisert [package insert]. Bridgewater, NJ: Bausch and Lomb Americas Inc, 2025.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.